Grail

Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase

Retrieved on: 
Thursday, July 22, 2021
Research, Medical devices, Genetics, Other Health, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Politics of the European Union, Foreign relations of the European Union, European Union, DNA sequencing, Grail, Illumina, Inc., Competition law, Illumina, European Economic Area, European Union merger law

We look forward to presenting our position during the Phase II process, said Charles Dadswell, General Counsel for Illumina.

Key Points: 
  • We look forward to presenting our position during the Phase II process, said Charles Dadswell, General Counsel for Illumina.
  • Illumina is also challenging the ECs jurisdiction to investigate the transaction under Article 22 of the European Union (EU) Merger Regulation.
  • Illumina has filed an action in the General Court of the EU seeking annulment of the ECs jurisdiction to review the acquisition.
  • Illuminas re-acquisition of GRAIL means that millions of citizens across the European Economic Area (EEA) will be able to access life-saving early cancer screening years sooner.

Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Oncology, Clinical medicine, Medicine, Branches of biology, DNA, Grail, Medical genetics, Anatomical pathology, Biopsy, Liquid biopsy, Hepatocellular carcinoma, Exact Sciences, DNA methylation

Grail is developing multi-cancer early detection liquid biopsy test or blood test which can detect up to 50 types of cancer and is committed to is committed to develop a deep understanding of cancer biology.

Key Points: 
  • Grail is developing multi-cancer early detection liquid biopsy test or blood test which can detect up to 50 types of cancer and is committed to is committed to develop a deep understanding of cancer biology.
  • GRAIL is poised to detect cancer early by combining high-intensity sequencing of unprecedented breadth and depth with the techniques of modern data science.
  • DNA methylation based liquid biopsy test: Exact Sciences
    Exact's DNA methylation based liquid biopsy test detects 80% of hepatocellular carcinoma (HCC) cases across all stages and 71% of early stage cases.
  • Liquid Biopsy for Cancer Diagnostics: Commercialization Activity
    This segment of the report provides a detailed list of any commercial activity in the field of liquid biopsy products ranging from collaboration, mergers and acquisition, recent breakthrough among others.

First Performance of The Holy Grail in Valencia by Multi-Media Artist Dr. María Gómez

Retrieved on: 
Wednesday, June 9, 2021
Web browsers, Holy Grail, Route of the Borgias, Valencia, Mara, Grail

The Mediterranean city of Valencia has kept the Holy Grail in its metropolitan Cathedral since 1437 and has ended the special fortnight with a spectacular artistic event.

Key Points: 
  • The Mediterranean city of Valencia has kept the Holy Grail in its metropolitan Cathedral since 1437 and has ended the special fortnight with a spectacular artistic event.
  • The multi-media artist, Dr. Mara Gmez dazzled the public with an artistic performance surrounded by expert plastic artists, art critics and the public.
  • Undoubtedly, she is the best international artist who has captured the history of the Holy Grail in images.
  • Mara Gmez can execute with the same iconographic motif a summary of the most important artistic movements that have created an entire European cultural heritage.

Guardian Research Network Celebrates Debut of New Early Cancer Detection Test

Retrieved on: 
Friday, June 4, 2021
Grail, Granulin, Cancer

SPARTANBURG,S.C., June 4, 2021 /PRNewswire/ --Guardian Research Network (GRN) today recognized the debut of a groundbreaking multi-cancer early detection (MCED) test called Galleri.

Key Points: 
  • SPARTANBURG,S.C., June 4, 2021 /PRNewswire/ --Guardian Research Network (GRN) today recognized the debut of a groundbreaking multi-cancer early detection (MCED) test called Galleri.
  • "GRN and our partners are gratified to be a major contributor to GRAIL's landmark Circulating Cell-free Genome Atlas (CCGA) study that will help improve lives through early detection," said Mark L. Watson, M.D., Ph.D., chief operating officer at Guardian Research Network.
  • The ability to detect cancer early is critical, as cancer is expected to become the leading cause of death in the U.S. this year.
  • GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured.

GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO Annual Meeting and Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Practice Management, Other Health, Health, General Health, Oncology, Medical devices, Research, Hospitals, Science, Clinical trials, Grail, Cancer screening

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today presented the first results from the interventional PATHFINDER study evaluating Galleri, a multi-cancer early detection (MCED) blood test.

Key Points: 
  • GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today presented the first results from the interventional PATHFINDER study evaluating Galleri, a multi-cancer early detection (MCED) blood test.
  • The results, presented at the 2021 ASCO Annual Meeting, support Galleris performance in clinical settings.
  • These results are a pivotal step toward extending early detection to many more types of cancer.
  • GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection.

Escalent Acquires Grail Insights

Retrieved on: 
Tuesday, June 1, 2021
Automotive Manufacturing, Other Consumer, Manufacturing, Other Health, Automotive, Telecommunications, Software, Finance, Consulting, Consumer, Data management, Professional services, Technology, Marketing, Advertising, Health, Communications, Other Automotive, Spacecraft, Articles, Holy Grail, Grail, Analytics, Grail, Spaceflight, Escalent, Grail, NewQuest Capital Partners, ESCALENT, GRAIL, NEWQUEST CAPITAL PARTNERS

Top human behavior and analytics advisory firm Escalent announces today it has acquired Grail Insights from NewQuest Capital Partners.

Key Points: 
  • Top human behavior and analytics advisory firm Escalent announces today it has acquired Grail Insights from NewQuest Capital Partners.
  • View the full release here: https://www.businesswire.com/news/home/20210601005662/en/
    Escalent announces today it has acquired Grail Insights from NewQuest Capital Partners.
  • In a world marked by disruptionwhere information, analysis, knowledge or guidance isnt always enoughEscalent and Grail have joined forces to advance insights through implementation, said Escalent CEO Melissa Sauter.
  • There will be no change to the Grail name in the near term, but Grail will be transitioned to the Escalent brand in the coming months.

Illumina Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition

Retrieved on: 
Thursday, April 29, 2021
Medical devices, Health, Professional services, Legal, Oncology, Biology, Branches of biology, Genomics, DNA sequencing, Illumina, Inc., Microarrays, Biotechnology, DNA, Molecular biology, Grail

b'Illumina, Inc. (NASDAQ: ILMN) announced today that it has filed an action in the General Court of the European Union asking for annulment of the European Commission\xe2\x80\x99s decision asserting jurisdiction to review Illumina\xe2\x80\x99s acquisition of GRAIL.

Key Points: 
  • b'Illumina, Inc. (NASDAQ: ILMN) announced today that it has filed an action in the General Court of the European Union asking for annulment of the European Commission\xe2\x80\x99s decision asserting jurisdiction to review Illumina\xe2\x80\x99s acquisition of GRAIL.
  • \xe2\x80\x9cThe Commission\xe2\x80\x99s actions will stifle innovation, fail patients and increase healthcare costs by needlessly delaying this transaction.
  • Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets.
  • Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Multi-Cancer Early Detection (MCED) Consortium to Chart Path Forward for Use of New Technologies to Improve Early Cancer Detection

Retrieved on: 
Thursday, April 22, 2021
Dana–Farber Cancer Institute, Harvard Medical School, Cancer research, Cancer Support Community, Grail, Health care, Health, Medicine

Over 35 organizations have contributed to the formation of the consortium, including initial founding members Blue Cross and Blue Shield Association (BCBSA) ; the Cancer Support Community ; Dana-Farber Cancer Institute , Inc.; Friends of Cancer Research ; GRAIL, Inc .

Key Points: 
  • Over 35 organizations have contributed to the formation of the consortium, including initial founding members Blue Cross and Blue Shield Association (BCBSA) ; the Cancer Support Community ; Dana-Farber Cancer Institute , Inc.; Friends of Cancer Research ; GRAIL, Inc .
  • "\n"We are very excited to help found the MCED consortium," said Kim Thiboldeaux, executive chair of the Cancer Support Community.
  • We look forward to collaborating with others in the cancer research community to identify how MCED can best be applied to help patients.
  • "Skip" Burris, III, MD,president of clinical operations and chief medical officer at Sarah Cannon Research Institute.

Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Retrieved on: 
Tuesday, April 20, 2021
Research, Technology, Medical devices, Genetics, Other Technology, General Health, Health, Science, Oncology, Other Science, Microarrays, DNA sequencing, Technology, Businesspeople, Illumina, Inc., Grail, Biology, Francis deSouza, Lumi

b'Illumina, Inc. (NASDAQ: ILMN), today announced that it disagrees with the European Commission\xe2\x80\x99s Directorate-General for Competition\xe2\x80\x99s decision to review Illumina\xe2\x80\x99s acquisition of GRAIL, a company founded to accelerate early screening of cancer.

Key Points: 
  • b'Illumina, Inc. (NASDAQ: ILMN), today announced that it disagrees with the European Commission\xe2\x80\x99s Directorate-General for Competition\xe2\x80\x99s decision to review Illumina\xe2\x80\x99s acquisition of GRAIL, a company founded to accelerate early screening of cancer.
  • Illumina will continue to work with the Directorate-General to bring the investigation to conclusion.
  • Illumina remains committed to the transaction, the impact of which would accelerate the adoption of a multi-cancer early detection blood test.\n\xe2\x80\x9cReuniting GRAIL and Illumina will allow us to bring GRAIL\xe2\x80\x99s breakthrough early detection multi-cancer test to patients across the world faster and consequently save lives,\xe2\x80\x9d said Francis deSouza, Chief Executive Officer of Illumina.
  • Together with GRAIL, Illumina looks forward to changing the course of cancer detection and treatment.\nIllumina is improving human health by unlocking the power of the genome.

Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Retrieved on: 
Tuesday, March 30, 2021
Oncology, Health, Genetics, Other Science, Research, Science, Biotechnology, Microarrays, Businesspeople, Technology, DNA sequencing, Illumina, Inc., Grail, Francis deSouza, Biology, Lumi, Illumina, Cancer screening

Illumina will pursue its right to proceed with the transaction, the impact of which would accelerate the adoption of a breakthrough multi-cancer early detection blood test.

Key Points: 
  • Illumina will pursue its right to proceed with the transaction, the impact of which would accelerate the adoption of a breakthrough multi-cancer early detection blood test.
  • Improving early cancer detection is the most promising approach to bending the cancer mortality curve, said Francis deSouza, Chief Executive Officer of Illumina.
  • Illumina strongly believes that acquiring GRAIL is in the best interest of patients, is procompetitive, and benefits the multi-cancer early detection field as a whole.
  • Illumina intends to pursue all legal options in order to complete the acquisition and deliver the strategic benefits to its stakeholders.